Phase II Study of Weekly Paclitaxel by 1-HR Infusion plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: A trial of the ECOG-ACRIN Cancer Research Group (E1898)

INTRODUCTION: This multi-center phase II study assessed the combination of estramustine and weekly paclitaxel with metastatic castrate resistant prostate cancer (CRPC). METHODS: We enrolled 77 patients who had no prior chemotherapy for CRPC between 1998 and 2000. 74 were eligible. Each 8-week cycle...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Genitourin Cancer
Autori principali: Wong, Yu-Ning, Manola, Judith, Hudes, Gary R., Roth, Bruce J., Moul, Judd W., Barsevick, Andrea M., Scher, Richard M., Volk, Michael J., Vaughn, David J., Williams, Stephen D, Fisch, Michael J., Cella, David, Carducci, Michael A, Wilding, George
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5975965/
https://ncbi.nlm.nih.gov/pubmed/29173976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.10.001
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi